Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

See all formats and pricing


Select Volume and Issue


Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis

Judit Marsillach1 / Cristina Oliveras-Ferraros2, 3 / Raúl Beltrán1 / Anna Rull1 / Gerard Aragonès1 / Carlos Alonso-Villaverde1 / Alejandro Vázquez-Martín2, 3 / Jorge Joven1 / Javier A. Menéndez2, 3 / Jordi Camps1

1Centre de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain

2Division of Catalonia, Catalan Institute of Oncology (ICO) Health Services, Spain

3Girona Biomedical Research Institute (IdIBGi), Dr. Josep Trueta University Hospital of Girona, Spain

Corresponding author: Jordi Camps, PhD, Centre de Recerca Biomèdica, Hospital Universitari de Sant Joan, C. Sant Joan s/n, 43201 Reus (Catalunya), Spain

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 47, Issue 9, Pages 1097–1099, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2009.259, September 2009

Publication History



Background: Fatty acid synthase (FASN) is an enzyme synthesized by the liver and plays an important role in lipogenesis. The present study aimed to assess whether serum FASN concentrations are altered in patients with chronic liver disease, and to investigate whether its measurement may be a useful tool in the clinical evaluation of this derangement.

Methods: We investigated 93 patients with chronic liver disease (14 minimal change disease, 79 steatohepatitis) and 100 control subjects. Serum FASN concentrations were measured using ELISA.

Results: Patients had a significant increase in serum FASN concentration (p<0.001), which was specifically associated with the hepatic Knodell sub-index III of portal inflammation (p=0.019). In addition, serum FASN concentrations were significantly correlated with the circulating levels of the monocyte chemoattractant protein-1 (MCP-1) (Spearman ρ=0.375; p<0.001) and type III procollagen-N-peptide (P-III-P) (Spearman ρ=0.297; p<0.001).

Conclusions: Serum FASN concentrations are increased in patients with chronic liver impairment, and are associated with specific histological alterations and biochemical markers of portal inflammation. These data suggest that FASN measurement may contribute significantly to the evaluation of these patients.

Clin Chem Lab Med 2009;47:1097–9.

Keywords: chronic hepatitis; fatty acid synthase; fibrogenesis; inflammation; steatosis

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Jorge Joven, Eugenia Espinel, Anna Rull, Raúl Beltrán-Debón, Gerard Aragonès, Esther Rodríguez-Gallego, Jordi Camps, Juan Pedro-Botet, Teresa Sans, Javier A. Menéndez, and Carlos Alonso-Villaverde
Journal of Clinical Virology, 2011, Volume 51, Number 3, Page 199
Karen M Kassel, Grace L Guo, Ossama Tawfik, and James P Luyendyk
Laboratory Investigation, 2010, Volume 90, Number 12, Page 1794

Comments (0)

Please log in or register to comment.